Patient With RRMM, Cytopenias, COPD, and Progressive Bone Disease
October 21st 2025Panelists discuss how a triple class–exposed patient with comorbidities like COPD represents an ideal candidate for BCMA-directed bispecific therapy over CAR T-cell therapy due to the ability to titrate dosing and manage respiratory infection risks.
Operationalizing Step-Up Dosing in Outpatient and Inpatient/Outpatient Hybrid Setting
October 14th 2025Panelists discuss how step-up dosing has successfully transitioned from inpatient-only to hybrid and outpatient models using prophylactic tocilizumab and standardized protocols for managing cytokine release syndrome.
Safety Strategies for GPRC5D-Directed and T-Cell Engager Therapies
October 14th 2025Panelists discuss how talquetamab’s unique skin and taste toxicities are manageable through dose modifications and supportive care, with IVIG prophylaxis being crucial for BCMA-targeted but not necessarily GPRC5D-targeted therapies.
Real-World Efficacy and Safety Protocols for Bispecific Antibodies
October 7th 2025Panelists discuss how real-world data consistently show bispecific efficacy matching clinical trial results despite treating higher-risk patients, and how prophylactic interventions have reduced cytokine release syndrome severity.
Sequencing Strategies and Patient Selection for Bispecific Antibodies in RRMM
October 7th 2025Panelists discuss how CAR T-cell therapy should generally precede bispecifics when possible due to T-cell exhaustion concerns, though they agree there are virtually no absolute contraindications to bispecific therapy.
Navigating Novel Therapies: ADCs, BsAbs, and CAR T in RRMM
September 30th 2025Panelists discuss how bispecifics are reversing the historical paradigm of diminishing returns in relapsed/refractory multiple myeloma, achieving 60% to 70% response rates lasting over a year in heavily pretreated patients.
Treatment Decision-Making in Multiple Myeloma at First and Subsequent Relapses
September 30th 2025Panelists discuss how patient preferences for treatment-free intervals are increasingly important in therapy selection, with bispecifics offering potential for response-adapted dosing and early discontinuation while maintaining remissions.
Navigating High-Risk Disease in Multiple Myeloma: Treatment Strategies and the Role of ASCT
January 19th 2024Experts dive into the complexities of defining and treating high-risk Multiple Myeloma (MM) and discuss the role of ASCT in newly diagnosed MM and weigh the considerations for recommending transplants, including insights on the selection criteria for tandem transplantations.
Defining Success in Multiple Myeloma Induction and Maintenance
January 12th 2024Three physicians explore the criteria for determining an adequate or successful response during the induction phase in patients with TE NDMM and uncover the intricate considerations shaping the choice of maintenance regimens.
Cross Q&A: Isa + KD in Relapsed/Refractory MM and Biochemical vs Clinical Progression
In the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.
Biochemical vs Clinical Progression in Relapsed/Refractory Multiple Myeloma
Expert Wilson Gonsalves, MD, shares clinical data in multiple myeloma centered on the distinction between biochemical versus clinical progression.
Cross Q&A: Real-World Use of Low-Dose Dasatinib in CML
Following a review of data with low-dose dasatinib in chronic myeloid leukemia, key opinion leaders from the Mayo Clinic and UT Southwestern consider its role in real-world practice.
Chronic Myeloid Leukemia: Long-Term Follow-up of Low-Dose Dasatinib
In the last presentation of the session, Abhishek Mangaonkar, MBBS, details clinical trial data with low-dose dasatinib in patients with chronic myeloid leukemia.
Relapsed/Refractory Multiple Myeloma: The IKEMA Study
Covering the first of two abstracts, Wilson Gonsalves, MD, reviews data from the IKEMA study of isatuximab KD in patients with relapsed/refractory multiple myeloma.
Cross Q&A: Role of Olverembatinib in Heavily Pretreated CML
In this cross Q&A, both the Mayo Clinic and UT Southwestern teams share insight on the role of olverembatinib in relapsed/refractory chronic myeloid leukemia.
Cross Q&A: Isatuximab + Pom-Dex in Relapsed/Refractory Multiple Myeloma
Panelists from both the Mayo Clinic and UT Southwestern comment on data from ALLIANCE A061202 and consider the role of isatuximab in patients with relapsed/refractory multiple myeloma.
Olverembatinib Study in Patients With Heavily Pretreated Chronic Myeloid Leukemia
A comprehensive review of chronic myeloid leukemia olverembatinib data led by expert Kebede Begna, MD, from the Mayo Clinic team.
Relapsed/Refractory Multiple Myeloma: The ALLIANCE A061202 Study
Adeel Khan, MD, MPH, MS, expert in multiple myeloma management, reviews data from the ALLIANCE A061202 trial of isatuximab + pomalidomide + dexamethasone in relapsed/refractory disease.
Cross Q&A: Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Experts from the Mayo Clinic and UT Southwestern share insight on the CARTITUDE-4 study and ciltacabtagene autoleucel in the second cross Q&A session.
Cross Q&A: Arterial Occlusive Events With Ponatinib in the PACE Trial
Following a review of the retrospective analysis of PACE, experts reflect on its importance in understanding the risk of arterial occlusive events with ponatinib.
Relapsed/Refractory Multiple Myeloma: The CARTITUDE-4 Study
Key opinion leader Prashant Kapoor, MD, FACP, shares data from the CARTITUDE-4 study of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.
Chronic Myeloid Leukemia: Retrospective Analysis of the PACE Study
A focused discussion led by expert Abhishek Mangaonkar, MBBS, on a retrospective analysis elucidating arterial occlusive events within the PACE study.
Cross Q&A: Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma
Panelists follow up with questions and comments on the KarMMa-3 study in relapsed/refractory multiple myeloma and consider how idecabtagene vicleucel might fit into real-world practice.
Cross Q&A: Ponatinib Dosing in Relapsed/Refractory Chronic-Phase CML
Expert perspectives from the Mayo Clinic and UT Southwestern teams on applications of the OPTIC study and optimal ponatinib dosing in chronic myeloid leukemia.